Does vancomycin have a future in the treatment of skin infections?

Current Opinion in Infectious Diseases

Volumn 27, Issue 2, 2014, Pages 146-154

  O'Brien, Deirdre J ^a   Gould, Ian M ^a  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

Author keywords

meticillin resistant Staphylococcus aureus; outpatient antimicrobial therapy; skin and soft tissue infection; vancomycin

Indexed keywords

CEFTAROLINE; CEPHALOSPORIN; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; LINEZOLID; OXAZOLIDINONE DERIVATIVE; TEDIZOLID; TIGECYCLINE; VANCOMYCIN;

DOSE RESPONSE; DRUG DISTRIBUTION; HUMAN; META ANALYSIS (TOPIC); MINIMUM INHIBITORY CONCENTRATION; REVIEW; SKIN INFECTION; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; HUMANS; MICROBIAL SENSITIVITY TESTS; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; VANCOMYCIN;

EID: 84896707931     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000048     Document Type: Review

References (70)

1. Bal AM, Garau J, Gould IM, et al. Vancomycin in the treatment of meticillinresistant Staphylococcus aureus (MRSA) infection: End of an era? Journal of Global Antimicrobial Resistance 2013; 1:23-30.
2. Gould IM. Is vancomycin redundant for serious staphylococcal infection? Int J Antimicrob Agents 2010; 36:S55-S57.
3. van Hal SJ, Fowler VG Jr. Is it time to replace vancomycin in the treatment methicillin resistant Staphylococcus aureus infections? Clin Infect Dis 2013; 56:1779-1788.
4. Holmes NE, Johnson PD, Howden BP. Relationship between vancomycinresistant Staphylococcus aureus, vancomycin intermediate S. aureus, high vancomycin MIC and outcome in serious S. aureus infections. J Clin Microbiol 2012; 50:2548-2552.
5. Kullar R, Davis SL, Levine DP, et al. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis 2011; 52:975-981.
6. Soriano A, Marco F, Martinez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46:193-200.
7. Rybak MJ, Vidaillac C, Sader HS, et al. Evaluation of vancomycin susceptibility testing for methicillin-resistant Staphylococcus aureus: comparison of Etest and three automated testing methods. J Clin Microbiol 2013; 51:2077-2081.
8. van Hal SJ, Barbagiannakos T, Jones M, et al. Methicillin-resistant Staphylococcus aureus vancomycin susceptibility testing methodology correlations, temporal trends and clonal patterns. J Antimicrob Chemother 2011; 66:2284-2287.
9. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillinresistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:18-55.
10. van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis 2012; 54:755-771.
11. Mavros MN, Tansarli GS, Vardakas KZ, et al. Impact of vancomycin minimum inhibitory concentration on clinical outcomes of patients with vancomycinsusceptible Staphylococcus aureus infections: a meta-analysis and metaregression. Int J Antimicrob Agents 2012; 40:496-509.
12. Murray KP, Zhao JJ, Davis SL, et al. Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg/L: a matched cohort study. Clin Infect Dis 2013; 56:1562-1569.
13. Jacob JT, DiazGranados CA. High vancomycin minimum inhibitory concentration and clinical outcomes in adults with methicillin-resistant Staphylococcus aureus infections: a meta analysis. Int J Infect Dis 2013; 17:93-100.
14. Hsu DI, Hidayat LK, Quist R, et al. Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictibility for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections. Int J Antimicrob Agents 2008; 32:378-385.
15. Bland CM, Porr WH, Davis KA, et al. Vancomycin MIC susceptibility testing of methicillin-resistant Staphylococcus aureus isolates: a comparison between Etest and an automated testing method. Southern Med J 2010; 103:1124-1128.
16. Ludwig F, Edwards B, Lawes T, et al. Effects of storage on vancomycin and daptomycin MIC in susceptible blood isolates of methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2012; 50:3383-3387.
17. Edwards B, Milne K, Lawes T, et al. Is vancomycin MIC 'creep' method dependent? Analysis of methicillin-resistant Staphylococcus aureus susceptibility trends in blood isolates from North East Scotland from 2008 to 2010. J Clin Microbiol 2012; 50:318-325.
18. Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355:653-665.
19. Méhes L, TaskóS, Székely A. Phagocytosis and intracellular killing of heterogeneous vancomycin-intermediate Staphylococcus aureus strains. J Med Microbiol 2012; 61:198-203.
20. Hafer C, Lin Y, Komblum J, et al. Contribution of selected gene mutations to resistance in clinical isolates of vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2012; 56:5845-5851.
21. Chua KY, Howden BP, Jiang JH, et al. Population genetics and the evolution of virulence in Staphylococcus aureus. Infect Genet Evol 2013. [Epub ahead of print]
22. Cataldo MA, Tacconelli E, Grilli E, et al. Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis. J Antimicrob Chemother 2012; 67:17-24.
23. van Hal SJ, Paterson DL, Lodise TP. Reply to 'vancomycin-induced nephrotoxicity'. Antimicrob Agents Chemother 2013; 57:2436.
24. Horey A, Megenhagen KA, Mattappallil A. The relationship of nephrotoxicity to vancomycin trough serum concentrations in a veteran's population: a retrospective analysis. Ann Pharmacother 2012; 46:1477-1483.
25. Brown J, Brown K, Forrest A. Vancomycin AUC24/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillinresistant Staphylococcus aureus and its association with attributable mortality during hospitalisation. Antimicrob Agents Chemother 2012; 56:634-638.
26. Zelenitsky S, Rubinstein E, Ariano R. Vancomycin pharmacodynamics and survival in patients with methicillin-resistant Staphylococcus aureus-associated septic shock. Int J Antimicrob Agents 2013; 41:255-260.
27. Skhirtladze K, Hutschala D, Fleck T. Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery. Antimicrob Agents Chemother 2006; 50:1372-1375.
28. Duane TM, Weigelt JA, Puzniak LA. Linezolid and vancomycin in treatment of lower-extremity complicated skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus in patients with and without vascular disease. Surg Infect 2012; 3:147-153.
29. Frazee EN, Kuper PJ, Schramm GE. Effect of continuous venovenous hemofiltration dose on achievement of adequate vancomycin trough concentrations. Antimicrob Agents Chemother 2012; 56:6181-6185.
30. Petejova N, Martinek A, Zahalkova J. Vancomycin removal during low-flux and high-flux extended daily hemodialysis in critically ill septic patients. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2012; 156:342-347.
31. Claus BO, Hoste EA, Colpaert K. Augmented renal clearance is a common finding with worse clinical outcome in critically ill patients receiving antimicrobial therapy. J Crit Care 2013; 28:695-700.
32. Albur MS, Bowker K, Weir J, et al. Factors influencing the clinical outcome of methicillin-resistant Staphylococcus aureus bacteraemia. Eur J Clin Microbiol Infect Dis 2012; 31:295-301.
33. Martinez-Olondris P, Rigol M, Soy D. Efficacy of linezolid compared to vancomycin in an experimental model of pneumonia induced by methicillinresistant Staphylococcus aureus in ventilated pigs. Crit Care Med 2012; 40:162-168.
34. MacGowan AP. Pharmacokinetic and pharmacodynamics profile of linezolid in healthy volunteers and patients with Gram-positive infections. J Antimicrob Chemother 2003; 51 (Suppl 2):17-25.
35. Stein GE, Schooley S, Peloquin CA, et al. Linezolid tissue penetration and serum activity against strains of methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility in diabetic patients with foot infections. J Antimicrob Chemother 2007; 60:819-823.
36. Beekmann SE, Gilbert DN, Polgreen PM. Toxicity of extended courses of linezolid: results of an Infectious Diseases Society of America Emerging Infections Network survey. Diagn Microbiol Infect Dis 2008; 62:407-410.
37. Flamm RK, Farrell DJ, Mendes RE, et al. LEADER surveillance program results for 2010: an activity and spectrum analysis of linezolid using 6801 clinical isolates from the United States (61 medical centers). Diagn Microbiol Infect Dis 2012; 74:54-61.
38. Sánchez GM, De la Torre MA, Morales G, et al. Clinical outbreak of linezolidresistant Staphylococcus aureus in an intensive care unit. J Am Med Assoc 2010; 303:2260-2264.
39. Yue J, Dong BR, Yang M, et al. Linezolid versus vancomycin for skin and soft tissue infections. Cochrane Database Syst Rev 2013; 7:CD008056.
40. Watkins RR, Lemonovich TL, File TM Jr, et al. An evidence-based review of linezolid for the treatment of methicillin-resistant Staphylococcus aureus (MRSA): place in therapy. Core Evid 2012; 7:131-143.
41. Itani KMF, Biswas P, Reisman A, et al. Clinical efficacy of oral linezolid compared with intravenous vancomycin for the treatment of methicillin-resistant Staphylococcus aureus - complicated skin and soft tissue infections: a retrospective, propensity score matched, case-control analysis. Clin Ther 2012; 34:1667-1673.
42. Urbina O, Ferrandez O, Espona M, et al. Potential role of tedizolid phosphate in the treatment of acute bacterial skin infections. Drug Des Devel Ther 2013; 7:243-265.
43. Prokocimer P, Bien P, Munoz A, Aster R. Hematologic effects of TR-701, linezolid and placebo administered for 21 days in healthy subjects [abstract]. In: 48th Conference on Antimicrobial Agents and Chemotherapy; October 25-28, 2008; Washington DC.
44. Bien P, Prokocimer P, Munoz KA, Bohn J. The safety of 21-day multiple ascending oral doses of TR-701, a novel oxazolidinone prodrug antibiotic [abstract]. In: 19th European Congress of Clinical Microbiology and Infectious Diseases; May 16-19, 2009; Helsinki, Finland.
45. Prokocimer P, De Anda C, Fang E, et al. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. J Am Med Assoc 2013; 309:559-569.
46. Rybak MJ. The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria. Clin Microbiol Infect 2006; 12:24-32.
47. Phillips J, Cardile AP, Patterson TP, et al. Daptomycin-induced acute eosinophilic pneumonia: analysis of the current data and illustrative case reports. Scand J Infect Dis 2013; 45:804-808.
48. Sabol K, Patterson JE, Lewis JS, et al. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob Agents Chemother 2005; 49:1664-1665.
49. Rege S, Mohr J, Lamp KC, et al. Safety of daptomycin in patients completing more than 14 days of therapy: results from the Cubicin outcomes registry and experience. Int J Antimicrob Agents 2013; 41:421-425.
50. Brown JE, Fominaya C, Christensen KJ, et al. Daptomycin experience in critical care patients: results from a registry. Ann Pharmacother 2012; 46:495-502.
51. Aikawa N, Kusachi S, Mikamo H, et al. Efficacy and safety of intravenous daptomycin in Japanese patients with skin and soft tissue infections. J Infect Chemother 2013; 19:447-455.
52. Konychey A, Heep M, Moritz RK, et al. Safety and efficacy of daptomycin as first-line treatment for complicated skin and soft tissue infections in elderly patients, an open-label, multicentre, randomized phase lllb trial. Drugs Aging 2013; 30:829-836.
53. Gould IM, MiróJM, Rybak MJ. Daptomycin: the role of high-dose and combination therapy for Gram-positive infections. Int J Antimicrob Agents 2013; 42:202-210.
54. Sharma M, Riederer K, Chase P, et al. High rate of decreasing daptomycin susceptibility during the treatment of persistent Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis 2008; 27:433-437.
55. Patel D, Husain M, Vidaillac C. Mechanisms of in-vitro selected daptomycinnonsusceptibility in Staphylococcus aureus. Int J Antimicrob Agents 2011; 38:442-446.
56. Song Y, Rubio Y, Jayaswai RK, et al. Additional routes to Staphylococcus aureus daptomycin resistance as revealed by comparative genome sequencing, transcriptional profiling and phenotypic studies. PLoS ONE 2013; 8:e58469.
57. Mehta S, Singh C, Plata KB, et al. β-Lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives. Antimicrob Agents Chemother 2012; 56:6192-6200.
58. Rose WE, Schulz LT, Andes D, et al. Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity. Antimicrob Agents Chemother 2012; 56:5296-5302.
59. Bounthavong M, Zargarzadeh A, Hsu DI, et al. Cost-effectiveness analysis of linezolid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus: complicated skin and skin structure infection using Bayesian methods for evidence synthesis. Value Health 2011; 14:631-639.
60. Muralidharan G, Micalizzi M, Speth J, et al. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005; 49:220-229.
61. Ellis-Grosse EJ, Babinchak T, Dartois N, et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005; 41:S341-S353.
62. European Medicines Agency. Questions and Answers on the Review of Tygacil (Tigecycline): Outcome of a Renewal Procedure (17 February 2011). http://www.ema.europa.eu/docs/en-GB/document-library/Medicine-QA/human/000644/ WC500102228.pdf. [Accessed 14 November, 2013]
63. Corey GR, Wilcox M, Talbot GH. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis 2010; 51:641-650.
64. Friedland HD, O'Neal T, Biek D. CANVAS 1 and 2: analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections. Antimicrob Agents Chemother 2012; 56:2231-2236.
65. LouieA,CastanheiraM,LiuW,etal.Pharmacodynamicsofb-lactamaseinhibition by NXL104 in combination with ceftaroline: examining organisms with multiple types of b-lactamases. Antimicrob Agents Chemother 2012; 56:258-270.
66. Mendes RE, Tsakris A, Sader HS. Characterization of methicillin-resistant Staphylococcus aureus displaying increased MICs of ceftaroline. J Antimicrob Chemother 2012; 67:1321-1324.
67. Werth BJ, Steed ME, Kaatz GW. Evaluation of ceftaroline activity against heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin- intermediate methicillin-resistant S. aureus strains in an in vitro pharmacokinetic/pharmacodynamic model: exploring the 'seesaw effect'. Antimicrob Agents Chemother 2013; 57:2664-2668.
68. Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med 1992; 117:390-398.
69. Campbell ML, Marchaim D, Pogue JM. Treatment of methicillin-resistant Staphylococcus aureus infections with a minimal inhibitory concentration of 2mg/mL to vancomycin: old (trimethoprim/sulfamethoxazole) versus new (daptomycin or linezolid) agents. Ann Pharmacother 2012; 46:1587-1597.
70. Wood JB, Smith DB, Baker EH. Has the emergence of community-associated methicillin-resistant Staphylococcus aureus increased trimethoprim- sulfmethoxazole use and resistance?: a 10-year time series analysis. Antimicrob Agents Chemother 2012; 56:5655-5660.